CA2623197A1 - Glycosylated polypeptides produced in yeast mutants and methods of use thereof - Google Patents

Glycosylated polypeptides produced in yeast mutants and methods of use thereof Download PDF

Info

Publication number
CA2623197A1
CA2623197A1 CA002623197A CA2623197A CA2623197A1 CA 2623197 A1 CA2623197 A1 CA 2623197A1 CA 002623197 A CA002623197 A CA 002623197A CA 2623197 A CA2623197 A CA 2623197A CA 2623197 A1 CA2623197 A1 CA 2623197A1
Authority
CA
Canada
Prior art keywords
antibody
yeast
mutant
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002623197A
Other languages
English (en)
French (fr)
Inventor
Yu Geng
Robert James Luallen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROSCI Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2623197A1 publication Critical patent/CA2623197A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002623197A 2005-09-22 2006-09-22 Glycosylated polypeptides produced in yeast mutants and methods of use thereof Abandoned CA2623197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71995205P 2005-09-22 2005-09-22
US60/719,952 2005-09-22
PCT/US2006/037302 WO2007035930A2 (en) 2005-09-22 2006-09-22 Glycosylated polypeptides produced in yeast mutants and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2623197A1 true CA2623197A1 (en) 2007-03-29

Family

ID=37889571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002623197A Abandoned CA2623197A1 (en) 2005-09-22 2006-09-22 Glycosylated polypeptides produced in yeast mutants and methods of use thereof

Country Status (6)

Country Link
US (1) US8202523B2 (cg-RX-API-DMAC7.html)
EP (1) EP1934605B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009509970A (cg-RX-API-DMAC7.html)
CN (1) CN101313216A (cg-RX-API-DMAC7.html)
CA (1) CA2623197A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007035930A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
US20110117601A1 (en) * 2007-08-31 2011-05-19 Markus Haberger Glycosylation Profile Analysis
EP2918606B1 (en) * 2008-12-04 2018-07-11 Korea Research Institute of Bioscience and Biotechnology Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
US20100291540A1 (en) * 2009-05-12 2010-11-18 National Tsing Hua University Carbohydrate binding module and use thereof
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
CN101914458B (zh) * 2010-02-09 2013-03-13 北京万特尔生物制药有限公司 白假丝酵母(甘露糖蛋白质复合体)菌毛株
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
JP6131190B2 (ja) 2010-09-29 2017-05-17 オキシレイン ユーケー リミテッド リン酸化ｎ−グリカンの脱マンノシル化
US8986956B2 (en) 2010-11-04 2015-03-24 Korea Research Institute Of Bioscience And Biotechnology Method for producing human epidermal growth factor in large volume from yeast
US8396871B2 (en) 2011-01-26 2013-03-12 DiscoverReady LLC Document classification and characterization
US9667514B1 (en) 2012-01-30 2017-05-30 DiscoverReady LLC Electronic discovery system with statistical sampling
US10467252B1 (en) 2012-01-30 2019-11-05 DiscoverReady LLC Document classification and characterization using human judgment, tiered similarity analysis and language/concept analysis
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
US20150299690A1 (en) * 2012-12-10 2015-10-22 Bo Jiang Engineered lower eukaryotic host strains deficient in grr1 activity for recombinant protein
US9677105B2 (en) * 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP3077517B1 (en) * 2013-12-02 2018-10-17 DSM IP Assets B.V. Ice structuring protein
CN104725484B (zh) * 2013-12-19 2018-03-13 中国科学院微生物研究所 一种糖基化多肽及其制备方法和其应用
KR101750888B1 (ko) * 2014-09-23 2017-06-26 한국생명공학연구원 YlMpo1 과발현을 이용한 만노스인산화 증대 방법
MX2017009253A (es) * 2015-01-16 2017-10-12 Alder Biopharmaceuticals Inc Anticuerpos antiglicoproteina y usos de los mismos.
CN113201054B (zh) * 2021-05-21 2022-07-05 华南农业大学 蛋白FoUPE1在调控香蕉枯萎病菌致病力中的应用
CN115160417B (zh) * 2022-06-24 2023-06-02 西南大学 盔形毕赤酵母Glyco_hydro类分泌蛋白及其应用
CN116590371B (zh) * 2023-07-13 2023-10-17 智享生物(苏州)有限公司 一种降低中华仓鼠卵巢细胞中抗体高甘露糖型的细胞培养方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
DE3224788A1 (de) 1981-07-17 1983-02-03 South African Inventions Development Corp., Scientia, Pretoria,Transvaal Traegergebundenes immunogenes material
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5266478A (en) 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
US5854400A (en) 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
EP0295803B1 (en) 1987-05-29 1993-11-03 Shuzo Matsushita Monoclonal antibodies
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5763160A (en) 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5298419A (en) 1988-03-31 1994-03-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5614612A (en) 1990-03-09 1997-03-25 Haigwood; Nancy L. Purified gp120 compositions retaining natural conformation
US5798251A (en) 1990-05-29 1998-08-25 Cedars-Sinai Medical Center Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
US5914109A (en) 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
US5712373A (en) 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992007878A1 (en) 1990-10-26 1992-05-14 The Public Health Research Institute Of The City Of New York, Inc. Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5696238A (en) 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
WO1993012232A1 (en) 1991-12-10 1993-06-24 Dana Farber Cancer Institute Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6103238A (en) 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
DE4301932A1 (de) 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh Hefewirtsstämme mit Defekten in der N-Glycosylierung
DE69433422T2 (de) 1993-03-11 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Monoklonaler anti-hiv antikörper
DK0699077T3 (da) 1993-05-07 2002-01-21 Bio Merieux Inc Immunogele HIV-komplekser
CA2156718A1 (en) 1993-12-23 1995-06-29 Bruno Gander Immunological response potentiation process
ATE177843T1 (de) 1994-01-19 1999-04-15 Us Health Peptomere mit erhöhter immunogenizität
US5559010A (en) * 1994-04-04 1996-09-24 The Regents Of The University Of California Nutrient regulated gene expression systems
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
EP0871485B1 (en) 1995-07-21 2007-02-21 University Of Nebraska Board Of Regents COMPOSITIONS AND METHODS FOR CATALYZING HYDROLYSIS OF HIV gp120
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP2767401B2 (ja) 1995-11-17 1998-06-18 工業技術院長 酵母のマンノース−１−リン酸転移酵素遺伝子およびこれを利用するマンノース−１−リン酸含有酸性糖鎖の製造方法
ES2277339T3 (es) 1995-11-30 2007-07-01 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vacuna con adyuvante de aceite y metodo para su preparacion.
AU1834197A (en) 1996-01-30 1997-08-22 National Institutes Of Health, The Cells expressing both human cd4 and cxcr4
US6713069B1 (en) 1996-04-16 2004-03-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100637410B1 (ko) * 1999-08-19 2006-10-23 기린 비루 가부시키가이샤 신규한 효모 변이주 및 포유류형 당쇄를 함유하는당단백질의 제조방법
AU7089600A (en) 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
JP3905695B2 (ja) * 1999-08-31 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 分裂酵母の糖転移酵素遺伝子ｏｃｈ１
US6391567B1 (en) 2000-03-02 2002-05-21 New York University Identifying compounds inhibiting DC-sign facilitation of HIV into cells
WO2001088143A1 (en) * 2000-05-17 2001-11-22 Mitsubishi Pharma Corporation Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP2028275A3 (en) 2000-06-30 2009-05-06 VIB vzw Protein glycosylation modification in pichia pastoris
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP4464269B2 (ja) * 2002-04-26 2010-05-19 協和発酵キリン株式会社 哺乳類型糖鎖生産メチロトロフ酵母
US7252933B2 (en) * 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
US7250251B2 (en) 2002-09-09 2007-07-31 The J. David Gladstone Institutes Virion-based fusion assay
CA2504755C (en) * 2002-10-11 2010-12-14 University Of Maryland Biotechnology Institute Carbohydrate-based synthetic vaccines for hiv
AU2003301804A1 (en) 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
EP1417965A1 (en) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
WO2004050711A2 (en) * 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
EP1696864B1 (en) * 2003-12-24 2014-11-12 GlycoFi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
US7728106B2 (en) * 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
CA2647632C (en) * 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
JP5967861B2 (ja) * 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化

Also Published As

Publication number Publication date
EP1934605B1 (en) 2014-03-26
WO2007035930A2 (en) 2007-03-29
EP1934605A2 (en) 2008-06-25
JP2009509970A (ja) 2009-03-12
EP1934605A4 (en) 2008-12-17
CN101313216A (zh) 2008-11-26
WO2007035930A3 (en) 2007-11-29
US20080038286A1 (en) 2008-02-14
US8202523B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
US8202523B2 (en) Glycosylated polypeptides produced in yeast mutants and methods of use thereof
Luallen et al. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies
Kong et al. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity
Scanlan et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→ 2 mannose residues on the outer face of gp120
Scanlan et al. Exploiting the defensive sugars of HIV-1 for drug and vaccine design
US20100183669A1 (en) Mannose immunogens for HIV-1
JP2001502315A (ja) ウイルス感染を処置するための組成物および方法
NO300462B1 (no) Monoklonale antistoffer og peptider som kan anvendes til diagnose av HIV-infeksjoner
Luallen et al. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN
EP1425036A2 (en) Virus coat protein/receptor chimeras and methods of use
AU2002355966A1 (en) Virus coat protein/receptor chimeras and methods of use
US9790276B2 (en) Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
US7728106B2 (en) HIV-1 glycopeptides and derivatives; preparation and applications thereof
US5876716A (en) Method of using an antibody to the TN antigen for the inhibition of HIV infection
TW200819461A (en) Vaccine
Zhao et al. Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus
Liu et al. Altering the specificity of the antibody response to HIV gp120 with a glycoconjugate antigen
Luallen et al. Antibodies against Manα1, 2-Manα1, 2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains
Yang et al. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc
HK1124917A (en) Glycosylated polypeptides produced in yeast mutants and methods of use thereof
EP0511967B1 (en) Medicaments and methods for treating acquired immune deficiency syndrome (aids) and aids-related complex (arc) employing anti-carbohydrate antibodies
Dent Development of a lectin-Fc fusion protein with antiviral and anti-cancer activity.
Seabright The impact of sequence diversity on the glycan shield of HIV-1 immunogens
Cottrell Structure-based HIV immunogen design
Bonomelli Antigenic and immunomodulatory properties of HIV-1 gp120 N-linked glycosylation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140819